Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Trocio

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
The American Journal of Cardiology|July 4, 2015
Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United StatesMintu P Turakhia, Jason Shafrin, Katalin Bognar, et al.
BMC Women'S Health|August 15, 2015
Prevalence of menopausal symptoms among mid-life women: findings from electronic medical recordsMatthew Sussman, Jeffrey Trocio, Craig Best, et al.
Current Medical Research and Opinion|October 10, 2015
Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillationSteve Deitelzweig, Michael Evans, Eric Hillson, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 25, 2018
All-Cause, Stroke/Systemic Embolism-, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral AnticoagulantsSteve Deitelzweig, Xuemei Luo, Kiran Gupta, et al.
Drugs - Real World Outcomes|July 12, 2016
Use of Chronic Medications Among Patients with Non-Valvular Atrial FibrillationPaul T Kocis, Guodong Liu, Dinara Makenbaeva, et al.
Journal of Medical Economics|March 31, 2016
Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: An early viewLin Xie, Lien Vo, Allison Keshishian, et al.
Current Medical Research and Opinion|June 22, 2017
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare populationAlpesh Amin, Allison Keshishian, Jeffrey Trocio, et al.
Neurourology and Urodynamics|February 21, 2013
Clinical value of a patient-reported goal-attainment measure: the global development of self-assessment goal achievement (SAGA) questionnaire for patients with lower urinary tract symptomsVik Khullar, Monserrat Espuna-Pons, Daniela Marschall-Kehrel, et al.
Journal of Managed Care & Specialty Pharmacy|September 14, 2018
Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense PopulationKiran Gupta, Jeffrey Trocio, Allison Keshishian, et al.
International Urogynecology Journal|March 5, 2011
Goal attainment scaling in patients with lower urinary tract symptoms: development and pilot testing of the Self-Assessment Goal Achievement (SAGA) questionnaireLinda Brubaker, Vik Khullar, Elisabeth Piault, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
The American Journal of Cardiology|July 4, 2015
Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United StatesMintu P Turakhia, Jason Shafrin, Katalin Bognar, et al.
BMC Women'S Health|August 15, 2015
Prevalence of menopausal symptoms among mid-life women: findings from electronic medical recordsMatthew Sussman, Jeffrey Trocio, Craig Best, et al.
Current Medical Research and Opinion|October 10, 2015
Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillationSteve Deitelzweig, Michael Evans, Eric Hillson, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 25, 2018
All-Cause, Stroke/Systemic Embolism-, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral AnticoagulantsSteve Deitelzweig, Xuemei Luo, Kiran Gupta, et al.
Drugs - Real World Outcomes|July 12, 2016
Use of Chronic Medications Among Patients with Non-Valvular Atrial FibrillationPaul T Kocis, Guodong Liu, Dinara Makenbaeva, et al.
Journal of Medical Economics|March 31, 2016
Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: An early viewLin Xie, Lien Vo, Allison Keshishian, et al.
Current Medical Research and Opinion|June 22, 2017
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare populationAlpesh Amin, Allison Keshishian, Jeffrey Trocio, et al.
Neurourology and Urodynamics|February 21, 2013
Clinical value of a patient-reported goal-attainment measure: the global development of self-assessment goal achievement (SAGA) questionnaire for patients with lower urinary tract symptomsVik Khullar, Monserrat Espuna-Pons, Daniela Marschall-Kehrel, et al.
Journal of Managed Care & Specialty Pharmacy|September 14, 2018
Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense PopulationKiran Gupta, Jeffrey Trocio, Allison Keshishian, et al.
International Urogynecology Journal|March 5, 2011
Goal attainment scaling in patients with lower urinary tract symptoms: development and pilot testing of the Self-Assessment Goal Achievement (SAGA) questionnaireLinda Brubaker, Vik Khullar, Elisabeth Piault, et al.
Pageof 4